<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421887</url>
  </required_header>
  <id_info>
    <org_study_id>MOXI</org_study_id>
    <nct_id>NCT02421887</nct_id>
  </id_info>
  <brief_title>Males, Antioxidants, and Infertility Trial</brief_title>
  <acronym>MOXI</acronym>
  <official_title>Males, Antioxidants, and Infertility (MOXI) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the Males, Antioxidants, and Infertility (MOXI) Trial is to examine whether
      treatment of infertile males with an antioxidant formulation improves male fertility. The
      central hypothesis is that treatment of infertile males with antioxidants will improve sperm
      structure and function, resulting in higher fertilization rates and improved embryo
      development, leading to higher pregnancy and live birth rates. Findings from this research
      will be significant in that they will likely lead to an effective, non-hormonal treatment
      modality for male infertility. An effective treatment for men would also reduce the treatment
      burden on the female partner, lower costs, and provide effective alternatives to couples with
      religious or ethical contraindications to ART (Assisted Reproductive Technology). If
      antioxidants do not improve pregnancy rates, but do improve sperm motility and DNA integrity,
      they could allow for couples with male factor infertility to use less intensive therapies
      such as intrauterine insemination. Male fertility specialists currently prescribe
      antioxidants based on the limited data supporting their use. A negative finding, lack of any
      benefit, would also alter current treatment of infertile males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">June 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>up to 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage Rate</measure>
    <time_frame>up to 9 months</time_frame>
    <description>miscarriages per total number of pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pregnancy</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Time to pregnancy will be the chronologic time from randomization to pregnancy detection in days, in which the pregnancy is defined as a human Chorionic Gonadotropin (hCG) value over 5 on 2 separate occasions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Motile Sperm Count</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Samples will be assessed using a standard semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Deoxyribonucleic Acid (DNA) Fragmentation Index (DFI)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>DFI is the ratio of damaged sperm to total sperm. It is measured using Sperm Chromatin Structure Analysis (SCSA) which was performed on 5000 sperm per sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Semen Total Motility</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Samples assessed using a standard semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sperm Concentration</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Samples assessed using a standard semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Normal Morphology of Semen, Using World Health Organization (WHO) 5 Criteria</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Samples assessed using a standard semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Sperm Count</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Samples assessed using a standard semen analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>Antioxidant Supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antioxidant Supplement</intervention_name>
    <description>An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
    <arm_group_label>Antioxidant Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Couple

          -  12 or more months of infertility (primary or secondary)

          -  Heterosexual

          -  Cohabitating and able to have regular intercourse

        Male:

          -  ≥ 18 years of age

          -  At least one abnormal semen parameter on a semen analysis within the past 6 months:

               -  Sperm concentration ≤15 Million/ml

               -  Total motility ≤40%

               -  Normal morphology (Kruger) ≤4%

               -  DNA fragmentation (SCSA, DNA fragmentation index) &gt;25%

        Female:

          -  ≥18 years of age and ≤40 years of age

          -  For women ≥ 35 years of age, evidence of normal ovarian reserve as assessed by
             menstrual cycle day 3 (+/-2 days) FSH ≤10 IU/L with estradiol ≤ 70 pg/mL, AMH ≥ 1.0
             ng/mL, OR antral follicle count &gt;10 within one year prior to study initiation.

          -  Evidence of at least one patent fallopian tube as determined by an hysterosalpingogram
             or laparoscopy showing at least one patent fallopian tube or a saline infusion
             sonogram showing spillage of contrast material

          -  Regular cycles defined as ≥25 days and ≤35 days in duration

          -  Evidence of ovulation including biphasic basal body temperatures, positive ovulation
             predictor kits, or progesterone level ≥3 ng/ml.

        Exclusion Criteria:

          -  Couple:

               -  Previous sterilization procedures (vasectomy, tubal ligation). The prior
                  procedure may affect study outcomes.

               -  Planning in vitro fertilization in the next 6 months

        Male:

          -  Sperm concentration &lt; 5 million/mL on screening semen analysis

          -  Current use of a medication or drug that would affect reproductive function or
             metabolism (see Appendix C for list)

          -  Current multivitamin or herb use (requires 1 month wash-out)

          -  Current serious medical illnesses, such as cancer, heart disease, or cirrhosis

          -  Current use of anticoagulants

          -  Untreated hypothyroidism

          -  Uncontrolled diabetes mellitus

        Female:

          -  History of surgically or medically confirmed moderate or severe endometriosis

          -  Body mass index &gt;35 kg/m2

          -  Currently pregnant

          -  History of polycystic ovarian syndrome

          -  Current serious medical illnesses, such as cancer, heart disease, or cirrhosis

          -  History of systemic chemotherapy or pelvic radiation

          -  Current use of a medication or drug that would affect reproductive function or
             metabolism
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Eisenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institue of Child Health and Human Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nanette Santoro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Z Steiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael P Diamond, MD</last_name>
    <role>Study Director</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard S Legro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelle Cedars, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl R Hansen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Coutifaris, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heping Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keck School of Medicine of University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center - Women's Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://c2s2.yale.edu/rmn/</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <results_first_submitted>June 24, 2019</results_first_submitted>
  <results_first_submitted_qc>August 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared with other researchers through the NICHD DASH system. It will be available 6 months after publication of the primary results.</ipd_description>
    <ipd_time_frame>Following publication of the primary publication and when the de-identified data have been put into a format that is acceptable for DASH submission.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02421887/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antioxidant Supplement</title>
          <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antioxidant Supplement</title>
          <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" lower_limit="30.0" upper_limit="38.0"/>
                    <measurement group_id="B2" value="34.0" lower_limit="30.0" upper_limit="37.0"/>
                    <measurement group_id="B3" value="34.0" lower_limit="30.0" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth Rate</title>
        <time_frame>up to 15 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate</title>
          <units>percentage of live births</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Rate</title>
        <time_frame>up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Rate</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Miscarriage Rate</title>
        <description>miscarriages per total number of pregnancies</description>
        <time_frame>up to 9 months</time_frame>
        <population>Miscarriage rate is calculated per number of participants who became pregnant.</population>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Miscarriage Rate</title>
          <description>miscarriages per total number of pregnancies</description>
          <population>Miscarriage rate is calculated per number of participants who became pregnant.</population>
          <units>miscarriages</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pregnancy</title>
        <description>Time to pregnancy will be the chronologic time from randomization to pregnancy detection in days, in which the pregnancy is defined as a human Chorionic Gonadotropin (hCG) value over 5 on 2 separate occasions.</description>
        <time_frame>up to 7 months</time_frame>
        <population>Time to pregnancy is calculated only for subjects who obtained pregnancy during the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pregnancy</title>
          <description>Time to pregnancy will be the chronologic time from randomization to pregnancy detection in days, in which the pregnancy is defined as a human Chorionic Gonadotropin (hCG) value over 5 on 2 separate occasions.</description>
          <population>Time to pregnancy is calculated only for subjects who obtained pregnancy during the trial.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" spread="62.3"/>
                    <measurement group_id="O2" value="123.5" spread="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Motile Sperm Count</title>
        <description>Samples will be assessed using a standard semen analysis</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>Participants for which semen samples were analyzed at both Baseline and Month 3 visit are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Motile Sperm Count</title>
          <description>Samples will be assessed using a standard semen analysis</description>
          <population>Participants for which semen samples were analyzed at both Baseline and Month 3 visit are included in this outcome measure.</population>
          <units>million sperm per mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-13.2" upper_limit="9.9"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-11.8" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Deoxyribonucleic Acid (DNA) Fragmentation Index (DFI)</title>
        <description>DFI is the ratio of damaged sperm to total sperm. It is measured using Sperm Chromatin Structure Analysis (SCSA) which was performed on 5000 sperm per sample.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Participants for which semen samples were analyzed for DFI at both Baseline and Month 3 visit are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Deoxyribonucleic Acid (DNA) Fragmentation Index (DFI)</title>
          <description>DFI is the ratio of damaged sperm to total sperm. It is measured using Sperm Chromatin Structure Analysis (SCSA) which was performed on 5000 sperm per sample.</description>
          <population>Participants for which semen samples were analyzed for DFI at both Baseline and Month 3 visit are included in this outcome measure.</population>
          <units>percentage of damaged DNA to total DNA</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="14.3" upper_limit="28.3"/>
                    <measurement group_id="O2" value="21.1" lower_limit="14.1" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Semen Total Motility</title>
        <description>Samples assessed using a standard semen analysis</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Semen Total Motility</title>
          <description>Samples assessed using a standard semen analysis</description>
          <units>percentage of sperm with any motility</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="16.0"/>
                    <measurement group_id="O2" value="-1.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sperm Concentration</title>
        <description>Samples assessed using a standard semen analysis</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>Participants for which semen samples were analyzed at both Baseline and Month 3 visit are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sperm Concentration</title>
          <description>Samples assessed using a standard semen analysis</description>
          <population>Participants for which semen samples were analyzed at both Baseline and Month 3 visit are included in this outcome measure.</population>
          <units>million sperm per mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-12.0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="2.4" lower_limit="-9.0" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Normal Morphology of Semen, Using World Health Organization (WHO) 5 Criteria</title>
        <description>Samples assessed using a standard semen analysis</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>Participants for whom semen samples were analyzed for morphology at both Baseline and Month 3 visit are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Normal Morphology of Semen, Using World Health Organization (WHO) 5 Criteria</title>
          <description>Samples assessed using a standard semen analysis</description>
          <population>Participants for whom semen samples were analyzed for morphology at both Baseline and Month 3 visit are included in this outcome measure.</population>
          <units>percentage of sperm with normal morpholo</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0" lower_limit="-2.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Sperm Count</title>
        <description>Samples assessed using a standard semen analysis</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>Participants for which semen samples were analyzed at both Baseline and Month 3 visit are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Antioxidant Supplement</title>
            <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Sperm Count</title>
          <description>Samples assessed using a standard semen analysis</description>
          <population>Participants for which semen samples were analyzed at both Baseline and Month 3 visit are included in this outcome measure.</population>
          <units>million sperm per sample</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" lower_limit="-32.5" upper_limit="12.6"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-21.8" upper_limit="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data was collected from start of study drug through 30 days after the last dose of study medication, on average 7 months. Subjects completed a monthly diary where they reported any adverse events. They were also queried by study staff at each study visit about any adverse events since the last visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Antioxidant Supplement</title>
          <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Antioxidant Supplement: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Esther Eisenberg, NICHD Project Scientist</name_or_title>
      <organization>NICHD</organization>
      <phone>301-496-6516</phone>
      <email>esther.eisenberg@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

